Inhibition of TGF-β2 is also observed in the local inflammatory environment, as TGF-β2 antisense gene-modified therapeutic vaccine, known as belagenpumatucel-L, showed improved survival within 12 weeks of platinum-based chemotherapy in non-small cell lung cancer patients who received prior radiation [34]. This evidence concerns the gene TGFB2 and non-small cell lung carcinoma.